FDA Approves Dexcom’s Stelo System as First Over-the-Counter Continuous Glucose Monitor for Children Ages 2-18

September 13, 2026

RadioWHAT (Facebook) USA

Overview

The FDA has approved Dexcom’s Stelo system as the first over-the-counter (OTC) continuous glucose monitor (CGM) available for children aged 2 to 18 without a prescription. This device provides 15-minute glucose trend readings for up to 15 days via a sensor and smartphone app. The approval significantly expands access to diabetes management technology, enabling easier and continuous glucose monitoring for a broader patient population, including non-insulin users.

In Depth

Key Findings

On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted approval for Dexcom’s Stelo system, making it the first over-the-counter (OTC) continuous glucose monitoring (CGM) device available for children aged 2 to 18 without a prescription. This landmark decision drastically expands access to diabetes management technology, particularly for non-insulin-using individuals with diabetes and those simply seeking to understand their glucose patterns. Continuous and convenient monitoring allows for early detection of dangerously high or low glucose levels, thereby enhancing daily self-management capabilities.

Technical / Clinical Details

The Dexcom Stelo system consists of a small, disposable sensor worn on the skin, which transmits data via Bluetooth to a compatible smartphone application. The sensor can be worn for up to 15 consecutive days, providing glucose trend readings every 15 minutes. The user-friendly app displays current glucose levels, historical trends, and predictive glucose forecasts, enabling users to understand in real-time how factors like meals, exercise, and stress impact their blood sugar. FDA approval is backed by extensive clinical data, affirming Stelo’s accuracy, reliability, and safety for a wide age range, including pediatric populations. This technology empowers personalized behavioral changes by continuously visualizing glucose dynamics.

Background & Context

Historically, CGM technology has primarily been prescribed for insulin-dependent individuals. However, millions of people in the U.S. alone are prediabetic or have non-insulin-dependent Type 2 diabetes, who could significantly benefit from continuous glucose insights to prevent disease progression or establish healthier lifestyles. The OTC approval of the Stelo system democratizes CGM technology, opening pathways for more individuals to access personalized health information. This is expected to reduce the need for frequent clinic visits and increase opportunities for effective home-based self-management.

Strategic Significance & Outlook

The OTC approval of the Dexcom Stelo system will profoundly impact the diabetes management market. Beyond traditional diabetes care, CGM devices are now poised for broader adoption in general health and preventative medicine. Specifically, enabling children to engage with glucose management early can lead to improved long-term health outcomes. As competitors also pursue similar OTC product developments, Dexcom is expected to solidify its market leadership by focusing on enhanced user experience and additional features, such as the newly introduced meal logging, to shape the future of diabetes care.

Source: https://www.facebook.com/RadioWHAT/posts/the-fda-has-approved-dexcoms-stello-system-the-first-continuous-glucose-monitor-/1629448919193442/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.